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Abstract.
Background: Previous studies suggest that Huntingtin, the protein mutated in Huntington’s disease (HD), is required for
actin based changes in cell morphology, and undergoes stimulus induced targeting to plasma membranes where it interacts
with phospholipids involved in cell signaling. The small GTPase Rac1 is a downstream target of growth factor stimulation
and PI 3-kinase activity and is critical for actin dependent membrane remodeling.
Objective: To determine if Rac1 activity is impaired in HD or regulated by normal Huntingtin.
Methods: Analyses were performed in differentiated control and HD human stem cells and HD Q140/Q140 knock-in mice.
Biochemical methods included SDS-PAGE, western blot, immunoprecipitation, affinity chromatography, and ELISA based
Rac activity assays.
Results: Basal Rac1 activity increased following depletion of Huntingtin with Huntingtin specific siRNA in human primary
fibroblasts and in human control neuron cultures. Human cells (fibroblasts, neural stem cells, and neurons) with the HD
mutation failed to increase Rac1 activity in response to growth factors. Rac1 activity levels were elevated in striatum of 1.5-
month-old HD Q140/Q140 mice and in primary embryonic cortical neurons from HD mice. Affinity chromatography analysis
of striatal lysates showed that Huntingtin is in a complex with Rac1, p85 subunit of PI 3-kinase, and the actin bundling protein
-actinin and interacts preferentially with the GTP bound form of Rac1. The HD mutation reduced Huntingtin interaction
with p85.
Conclusions: These findings suggest that Huntingtin regulates Rac1 activity as part of a coordinated response to growth
factor signaling and this function is impaired early in HD.
Keywords: Actin, growth factor, GTPase, HTT, PI 3-kinase, “Ras-Related C3 Botulinum Toxin Substrate 1”, signaling
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INTRODUCTION
Huntingtin, the protein product of HTT, the gene
mutated in Huntington’s disease (HD) [1], has an
expanded polyglutamine tract. Huntingtin is required
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for embryonic survival [2–4] and its acute knock-
down in adult neurons causes degeneration [5–8].
Moreover, the presence of mutant Huntingtin dis-
rupts TrkA receptor signaling and neurite outgrowth
[9]. Collectively these findings suggest that Hunt-
ingtin influences cellular responses to growth factor
signaling.
Studies indirectly support Huntingtin’s involve-
ment in signaling through receptor tyrosine kinases
which drive actin dependent morphology changes.
Huntingtin preferentially associates with particular
phospholipids in vitro including phosphatidylinosi-
tol bis (3,4) phosphate and phosphatidylinositol tri
(3,4,5) phosphate (PI(3,4)P2 and PI(3, 4, 5)P3) [10,
11]. Stimulation of receptor tyrosine kinases activate
class IA PI 3-kinases causing a transient rise of PI(3,
4)P2 and PI(3, 4, 5)P3 [12, 13]. These phospholipids
in turn accumulate at local sites on the plasma mem-
brane and engage protein complexes that propagate
signal cascades directing cell morphology changes
driven by actin reorganization [14, 15]. Stimulation of
receptor tyrosine kinases by PDGF and IGF1 caused
Huntingtin to re-localize to the plasma membrane
[10] suggesting a functional role for Huntingtin in PI
3-kinase pathways. In PC12 cells, Huntingtin was co-
immunoprecipitated with TrkA receptors following
nerve growth factor stimulation and with p85 reg-
ulatory subunit of PI 3-kinase and Grb2 [9, 16]. The
interaction of Huntingtin with p85 was also iden-
tified in a yeast two-hybrid screen with Huntingtin
fragments [17, 18].
The small GTPases Rac1, 2 and 3 are members of
the Rho GTPase family and are important for actin-
based changes that propel cell motility, protrusion
formation and membrane ruffling [19]. Rac1 is known
to be a downstream target of growth factor receptor
/PI3kinase activity [14] and controls growth factor
initiated morphology changes [14]. Transcripts for
Rac1 are ubiquitously expressed whereas those for
Rac2 are restricted to T-, B- and hemopoietic cell lin-
eages [20, 21]. Rac3 transcripts are expressed most
prominently in brain tissue but also in heart, pan-
creas and placenta [22]. Thus, total Rac activity levels
may be due to contributions from more than one Rac
protein especially in brain.
Results of investigations into Huntingtin binding
partners using yeast two-hybrid or mass spectrometry
(MS) after Huntingtin immunoprecipitation suggest
that Huntingtin associates with proteins involved
in actin cytoskeletal regulation and function; this
includes actin itself [18, 23, 24]. In agreement with
these findings, a purified N-terminal Huntingtin frag-
ment directly interacted with actin in vitro via aa1–14
of Huntingtin [25]. In the nucleus, endogenous Hunt-
ingtin co-localized with actin and cofilin rods which
form upon stress and Huntingtin is necessary for
their formation; mutant Huntingtin has been shown
to alter actin/cofilin rods [26]. Other evidence that
mutant Huntingtin may impact actin related functions
includes the finding that mutant Huntingtin exon1
toxicity can be modulated by inhibiting the kinase
ROCK and its phosphorylation of the actin binding
protein profilin [27]. However, there has been limited
evidence linking endogenous Huntingtin localiza-
tion or function with cytoplasmic actin in cells
[18, 28].
Here we sought to determine in different wild-
type (WT) and HD models the molecular basis for
Huntingtin involvement in PI 3-kinase dependent
functions. Our results show that mutant Huntingtin
affects the activation of Rac1 and is in a complex
with the active form of Rac1, the p85 regulatory
subunit of PI-3 kinase, and -actinin-2, a protein
that crosslinks and bundles actin filaments [29, 30]
and is enriched in striatum and present in spines
[31].
MATERIALS AND METHODS
Animals
Brains from mice homozygous for a polyglutamine
expansion and human exon1 knock-in within the
endogenous mouse huntingtin genes (Hdh140Q/140Q)
[32] or WT mice with the same strain background
of C57BL/6 were bred at the MGH animal facil-
ity. Genotypes were determined by PCR of tail
DNA. Although named “Q140”, the average CAG
repeat length of this colony is now 128 CAGs due
to the instability at the locus. The animal proto-
col was approved by the MGH Subcommittee on
Research Animal Care (SRAC)-OLAW Assurance
# A3596–01. All procedures conform to the USD
Animal Welfare Act, the ‘ILAR Guide for the Care
and Use of Laboratory Animals’, PHS Policy on
Humane Care and Use of Laboratory Animals, [33,
34]. Prior to rapid dissections on ice, mice were
anesthetized with CO2 followed by cervical dis-
location. Striatal and cortical tissues were rapidly
frozen using liquid nitrogen then stored at –80◦C until
further use. Primary cortical neuron cultures were
prepared and cultured exactly as previously described
[35].
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Cell culture
Primary human fibroblasts were obtained from
Coriell Cell Repository and used within 10 passages.
Cell line number and CAG repeat on each allele are
as follows: GM08399, 17/19, WT; GM04837, 44/47,
HD; GM04855 20/50, HD; GM04281, 17/69, HD;
GM03440B, not determined, “unaffected” control.
Cells were cultured using recommended medium. For
PDGF experiments primary fibroblasts were made
quiescent by incubating in serum-free medium for
48 hours prior to the addition of 100 ng/ml PDGF-
BB (Biosource) for 15 min at 37◦C. The normal
culture medium includes additional essential and
non-essential amino acids. Cell serum starvation
in this enriched medium showed no evidence of
increased autophagy. The siRNAs targeting exon1
of HTT (named E1–4, 5’GACCCTGGAAAAGCT-
GATGAA’3) or GFP were previously described [36].
The sequence for GFP serves as a non-targeting
sequence since the sequence does not exist in
the human genome. Cells were plated in serum-
containing medium onto coverslips plated at 2500
cells/coverslip. SiRNAs were added to cells plated
at 2500 cells/coverslip at 20 nM (0.8L Dharma-
fect reagent per 200 uL serum-free medium) on
12 mm glass coverslips coated with poly-L-lysine
in serum-free medium containing siRNA for 48 hrs
then incubated for 15 min in serum-free medium con-
taining 100 ng/mL PDGF-BB (Gibco) or serum-free
medium alone (control).
Human induced pluripotent stem cells (IPSCs)
were acquired from NINDS Repository at the Coriell
Institute for Medical Research: Cat# ND38554
(abbreviated as WT54) with 17 CAGs; Cat# ND369
97 (abbreviated as WT97) with 32 CAGs; Cat#
ND38551 (abbreviated as HD51) with 50 CAGs;
Cat# ND38548 (abbreviated as HD48) with 41 CAGs.
Genotypes were verified by PCR amplification of
HTT locus in genomic DNA and by western blot.
IPSCs were grown on mouse embryonic fibrob-
lasts treated with mitomycin C in the following
medium: Knockout DMEM/F12 (Life Technolo-
gies #12660–012) supplemented with 20% knockout
serum replacement (Life Technologies #10828–028),
1 mM L-glutamine (Life Technologies #35050–061),
1x MEM non-essential amino acids (Life Technolo-
gies #11140–050), 100M 2-mercaptoethanol and
50 units/mL penicillin/streptomycin (Life Technolo-
gies #15070–063). Adherent human neural stem cells
(NSCs) were established as described [37–39] with
modifications. Briefly, IPSC colonies were dislodged
with 1 mg/mL collagenase type I (Life Technolo-
gies #17018–029) in DMEM (Life Technologies
#11995–073) and re-plated onto 0.1% gelatin
coated plates (Sigma #G1393) in NSC medium
containing Advanced DMEM/F12 (Life Technolo-
gies #12634–028) with 2 mM L-glutamine, 50
units/mL penicillin/streptomycin, retinoic acid-free
B27 supplement (Life Technologies #12587–010),
N2 supplement; supplemented with 100 ng/mL FGF
(Invitrogen #PHG0023), 100 ng/mL EGF (Invitro-
gen #PMG8041), 5g/mL heparin (Sigma #H3149),
and 1% knockout serum replacement. Bipolar cells
streamed out of colonies during the next 5–14 days.
When 60–80% confluent, cells were detached using
Accutase (Sigma, #A6964) for 2–5 min and pelleted
by centrifugation. Remaining cell clumps were dis-
rupted with a p1000 micropipette tip and all cells were
re-suspended in a single cell suspension and re-plated
onto 0.1% gelatin coated plastic in NSC media con-
taining 20 ng/mL FGF, 20 ng/mL EGF, and 5g/mL
heparin. Cells were passaged with Accutase as pre-
viously described 1:2–1:4 for the first four passages,
then 1:2–1:10 during later passages. NSCs were rou-
tinely tested for expression of the radial glial marker
Nestin by immunofluorescence and for normal and
mutant Huntingtin expression using anti-huntingtin
antibody Ab1 (against aa 1–17) by western blot.
Human neurons were differentiated from non-
disease and HD iPSCs using dual TGFbeta and
Smad inhibition and Activin A exactly as described
[40]; the main neuron type produced is GABAer-
gic with expression of DARPP32, characteristic of
medium spiny neurons (MSNs) which are highly
affected in HD. Using this procedure, we have about
80% cells positive for the neuronal marker Beta-III-
tubulin with immunofluorescence and no detectable
GFAP by western blot. To lower Huntingtin in human
neurons, 1 or 3M of a hydrophobically-modified
siRNA (HTT10150, [41]) directed to position 10150
in HTT mRNA or a non-targeting control (NTC) was
introduced into 38 day old neurons. Cultures were
harvested at 43 days for analysis by western blot for
huntingtin levels and for Rac activity.
Antibodies and cell stains
For western blot
Polyclonal anti-htt 1–17 Ab1(1g/ml) [42], mAb
1C2 to polyglutamines (MAB1574, 1:1000; Mil-
lipore), mAb 3B5H10 to polyglutamines (P1874,
1:10,000; Sigma), p85 PI 3-kinase (1:500; #4292,
Cell Signaling), AKT and phospho (Ser473) AKT
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(1:500; Cell Signaling); ERK and phospho ERK
(1:1000; Cell Signaling); -tubulin (1:4000; T8328,
Sigma), beta3-tubulin (1:2000; Sigma), anti-GFAP
(1:2000; Millipore), Rac1 (1:2000; Millipore), nestin
(1:500; Millipore), DARPP32 (1:5000; Abcam),
Islet1 (1:200; University of Iowa Developmental
Studies Hybridoma Bank), GAPDH (1:6000; Milli-
pore), -actinin-2 (1:250; mAb clone EA-53, Sigma)
or -actinin-2 (1:2000; ab68167; Abcam; [31], -
actinin (2g/ml; ab18061; Abcam; may cross react
with isoforms 1–4).
For ﬂuorescent labeling
Anti-Nestin (1:500; ABD69 rabbit polyclonal;
Millipore), anti-DARPP32 (1:200; [EP720Y]
ab40801 rabbit monoclonal; Abcam), and anti-BIII
Tubulin Isotype III (1:500; T8660 mouse mono-
clonal; Sigma). Secondary antibodies include Cy3
goat anti-mouse secondary antibody (1:500; Jackson
Immunoresearch); Cy3 goat anti-rabbit secondary
antibody (1:500; Jackson Immunoresearch); Bodipy
Green goat anti-mouse secondary antibody (1:500;
Invitrogen). Stains include DAPI (1:500 Sigma) for
nuclei.
Rac activity measurements
Rac activity was measured using ELISA-based
kits: a colorimetric assay measuring active Rac1, 2,
3 and a luminescence assay specifically measuring
active Rac1 (Cytoskeleton, Inc., Denver Colorado).
These assays quantify the amount of Rac binding
to the binding domain of its downstream effector,
p21-activated kinase and are measured by absorbance
at 490 nm or luminescence respectively on a Perkin
Elmer Victor plate reader [43]. Fibroblasts and NSCs
were grown to 50–70% confluence in 60 mm plates
then fresh medium was introduced either with no
growth factor but carrier, 100 ng/ml PDGF-BB, or
100 ng/ ml BDNF (Invitrogen) for 15 min at 37◦C.
Cells were then lysed in 150L in the kit lysis buffer
on ice after three washes with ice cold 1X PBS con-
taining 1 mM MgCl2 and 2 mM CaCl2. Mouse brain
tissues were homogenized in provided lysis buffer,
with the addition of three phosphatase inhibitors:
1 mM Na3VO4, 50 mM NaF and 20 mM Na4P2O7
and cleared by centrifugation for 1 min at 3,000 rpm.
All lysates and supernatants were snap frozen in liq-
uid nitrogen, and stored at –80◦C. Relative Rac1,2,
3 or Rac1 activity was measured per manufacturer
instructions (Cytoskeleton, Inc., Denver, Colorado).
Results are relative only to other samples run at the
same time on the same ELISA plate. For each exper-
imental set of lysates, samples were diluted to match
that with the lowest protein concentration using lysis
buffer, as per kit instructions. Thus, the exact amount
of protein used varied from experiment to experi-
ment. Equal volumes of lysates were loaded into 96
well plates pre-coated with the effector protein. Ini-
tial experiments were performed to determine that the
concentrations of cell lysates resulted in signal that
was above background and did saturate binding on the
ELISA plate. Positive and negative controls were run
for each experiment. All experimental results were
repeated at least twice, except in Fig. 3b (using dif-
ferentiated human neuronal cultures). Graphs show
results of representative experiments. For relative Rac
activity measurements from animals, WT and HD
male mice at 1.5 and 4.5 months were sacrificed
and processed randomly, but the investigator was not
blinded to genotype; Rac activation assays on lysates
from the same set of animals were performed in two
independent experiments each with three technical
replicates which were averaged for each animal.
Western blots and silver staining
Proteins were separated by SDS-PAGE using
3–8% Tris-acetate gels or 4–12% Tris-bis gels (Life
Technologies); proteins were transferred to nitrocel-
lulose using iBlot semi-dry transfer apparatus (Life
Technologies) and developed using ECL or gels were
stained using the Silver Stain Plus kit (BioRad).
Statistical analysis was performed using Microsoft
Excel or Prism (GraphPad Software). Pixel intensity
quantification of 16-bit images was performed using
ImageJ (NIH) and signal intensity for Huntingtin
was standardized to signal intensity for -tubulin or
GAPDH. The bands were manually traced in ImageJ
and the area and mean gray values of each band were
determined. Total signal intensity was calculated by
multiplying mean gray value by area to determine the
total pixel intensity per band.
Immunoprecipitations
Primary human fibroblasts were serum-starved
24–48 h, treated with 100 ng/ml PDGF for 7 min then
lysed in IP buffer at pH 7.4 (50 mM Tris, 150 mM
NaCl, 1 mM MgCl2, 1 mM NaF, 1 mM Na3VO4, 1%
NP 40, 10% glycerol) containing protease inhibitors
(complete midi EDTA-free, Roche). The IP buffer
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was chosen to maximize interactions with membrane
related signaling complexes [16]. 375g of lysates,
first pre-cleared with protein G-Sepharose 4-flastflow
(GE Healthcare), were incubated overnight at 4◦C
with 3l anti-Htt monoclonal antibody MAB2166,
clone 1HU-4C8 (Millipore). Lysates were incubated
2 h with protein-G-Sepharose then immune com-
plexes were washed 3x with IP buffer and 1x in PBS.
Immunoprecipitated proteins were eluted in 50l
sample buffer and analyzed by SDS-PAGE and west-
ern blot. For rapid IPs from mouse brain, the primary
antibody MAB2166 was first bound to protein-G
Sepharose for 3 h in IP buffer then pre-blocked with
2%BSA in PBS overnight at 4◦C. Brain tissues were
homogenized in IP buffer, protein concentrations
measured by Bradford Assay and 500g of lysate
per reaction were incubated with the whole antibody-
protein-G-Sepharose complex for 30 min on ice with
intermittent gentle shaking. Control reactions con-
taining pre-blocked protein-G-Sepharose and lysate
were included. Complexes were rapidly washed 3x
in ice-cold IP buffer, washed 1x in PBS and eluted
with 50l sample buffer.
Statistical analysis
Confocal images file names or slides were
encrypted and pixel intensity quantification and
morphology analyses was performed by blinded
observers. For animal studies, no statistical method
was used to predetermine sample size number, how-
ever, a posthoc power analysis (G Power software)
indicated n = 4 animals per group for the change
between WT and HD in striatum at 1.5 months was
Actual Power = 0.98. For comparisons of the same
cell line treated or untreated, a paired t-test was used.
For comparisons between two cell lines or two animal
genotypes, unpaired t-tests were used. For compar-
isons among multiple samples ANOVA and Tukey’s
HSD posthoc tests were performed in R or using
GraphPad Prism.
Afﬁnity chromatography
Control GST protein was expressed from pGEX-
6P-1-FLAG-tag, a gift from Erich Wanker [45].
pGEX-2T-Rac1-wt was a gift from Gary Bokoch
(Addgene plasmid # 12977). Plasmids were trans-
formed into E.Coli strain BL21 by heat shock and
plated onto LB agar, clones were isolated then grown
in LB broth plus ampicillin at 37◦C with shaking
until OD600 nm = 0.7, then cultures were induced
with 0.5 mM IPTG and incubated another 4 h with
shaking. Bacteria were collected by centrifugation at
4000x g for 45 min at 4◦C. Pellets were re-suspended
in 30 mL of buffer (10 mM Tris pH7, 50 mM NaCl,
50 mM KCl, 10% Glycerol) and centrifuged again at
10,000x g for 15 min at 4◦C. Pellets were preserved
at –20◦C until further use. Pellets were re-suspended
in 10 mL of buffer (10 mM Tris pH 8.0, 50 mM NaCl,
50 mM KCl, Glycerol 10%, Lysozyme 1 mg.L–1,
DTT 1 mM, 1 tablet of Complete™ Mini EDTA-
free). Suspensions were sonicated for 5 min (3 s “on”,
10 s “off”, amplitude of 40%). GST proteins were iso-
lated using a gravity flow column purification with
400L of Glutathione Sepharose 4B equilibrated
in the same buffer, washed with 5 volumes 10 mM
Tris pH 8.0, 50 mM NaCl, 50 mM KCl, Glycerol 10
%+Triton 0.5% followed by 5 volumes in the same
buffer excluding Triton, then eluted with Tris 10 mM
pH 8.0, 150 mM NaCl, 50 mM Glutathione. Frac-
tions were analyzed on NuPAGE® Bis-Tris gels with
MES buffer and evaluated for purity and integrity by
SDS-PAGE and Coomassie stain. Most concentrated
fractions were pooled and concentrated with Ami-
con Ultra-0.5 Centrifugal Filter Unit with Ultracel-3
membrane to ∼100L (13,000 rpm at 4◦C during
15 min to concentrate 500L to 100L). The con-
centrated solution was brought to the original sample
volume (∼500L) with phosphate buffer 50 mM,
pH7.4. This process of “washing out” was repeated
5 times (∼55 = 3,125 dilution fold) to realize buffer
exchange.
Affinity chromatography was based on methods
described by Christoforidis et al. [46]. For each con-
dition, 750g GST-Rac1 protein was incubated with
15l Glutathione Sepharose 4B beads in buffer 1 as
described with either 1 mM GTPS (Sigma G8634)
or 1 mM GDP (Sigma G7127) for 90 min at RT, then
stabilized in buffer 2 with 1 mM GTPS or GDP.
Snap frozen dissected tissue from striatum of WT
and HD Q140/Q140 mice at 1.5 months were lysed
into buffer 2 with the addition of protease inhibitors,
1 mM NaF, and 1 mM Na3VO4, and without GTPS
or GDP. Lysates were centrifuged at 3000 g for 5 min
to remove nuclei and supernatants (S1) were used for
experiments. S1 sample concentrations were deter-
mined by Bradford, and 500g of protein lysates
were added to each GST-RAC1[GTPgammaS] or
GST-RAC1[GDP] Glutathione sepharose complexes,
incubated ON at 4◦C. Beads were spun down and
flow through buffer (FT) was removed to avoid over-
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loading the column. Beads were re-suspended in
3 volumes (45l) buffer 2 and 10M GTPS or
GDP, and loaded onto a micro-spin column (Pierce
#89879). All spins were 2 min at 1000 g. Additional
washes were completed (45l, 30l, 30l) with
buffer 2 and 10M GTPS or GDP. Additional
washes 2 × 45l and 2 × 30l with buffer 2 con-
taining 250 mM NaCl and 10M GTPS or GDP.
One final wash was completed in 1 volume (15l)
(20 mM Hepes, 250 mM NaCl, 1 mm DTT, pH 7.5). A
total of 5 serial dilutions (10l each) were completed
using elution buffer (20 mM Hepes, 250 mM NaCl,
20 mM EDTA, 50 mM Glutathione, 1 mM DTT, pH
7.5). GTPS sample elution buffer additionally con-
tained 5 mM GDP, while GDP sample elution buffer
contained 1 mM GTPS. Input (S1), flow through
(FT) and five elution fractions (E1–5) were collected
and analyzed by SDS-PAGE, silver stain and western
blot analysis. WT brain was also incubated with GST
alone with GTPS or GDP buffers as controls.
RESULTS
Rac1 activity is impaired in HD ﬁbroblasts and is
positively regulated by Huntingtin lowering
Rac1 is involved in adhesion by promoting assem-
bly of vinculin and -actinin containing complexes
[47] and requires PI(3,4,5)P3 to promote actin
polymerization together with the WAVE regulatory
complex [48–50]. Since Huntingtin interacts prefer-
entially with lipid products of PI-3 kinase including
PI(3, 4, 5)P3 [10], we asked if the presence of the
HD mutation affected Rac activity. The ELISA assay
with a peroxidase-based readout that we used did
not discriminate between Rac1, Rac2 or Rac3 activ-
ity; however, northern blot studies show that Rac1
is ubiquitously expressed whereas Rac2 and 3 have
restricted tissue distribution [20–22]. Thus, it is likely
that the Rac activity measured in adult fibroblasts can
be attributed to Rac1. Rac1, 2, 3 activity in a normal
quiescent fibroblast line exposed to PDGF was signif-
icantly increased compared to no PDGF treatment as
expected (Fig. 1a). However, in response to PDGF,
Rac1, 2, 3 activity in three HD fibroblast cell lines
failed to increase significantly (Fig. 1a).
To determine if other downstream signaling targets
of PDGF receptor were also affected, phosphoryla-
tion levels of AKT and ERK were examined. Western
blot analysis showed normal levels of phosphoAKT
and phosphoERKs in total lysates of control and HD
fibroblasts in response to PDGF stimulation, except
for the phosphoAKT response to PDGF in one HD
line that had a very large CAG repeat in HTT (Sup-
plementary Figure 1a-d). These data indicate that
activation of PI 3-kinase occurs normally in human
HD fibroblasts since AKT requires the PI 3-kinase
products PI(3,4)P2 and PI(3,4,5)P3 for binding to
the plasma membrane where it is phosphorylated
by protein kinase D. To determine if the inability
to activate Rac1, 2, 3 in HD fibroblasts was due to
altered Rac1 protein levels, western blot analysis was
performed. Levels of Rac1 were not significantly dif-
ferent between control and HD cell lines, however
there was a trend for lower levels of Rac1 protein in
two of the HD cell lines with the higher CAG repeats
(20/50 and 17/69) (Supplementary Figure 1f).
To determine if Huntingtin is required for the activ-
ity of Rac1, 2, 3 we treated control human fibroblast
cells with siRNA targeting HTT mRNA. At 48 hours
post-transfection, western blot and pixel intensity
quantification analysis showed that treatment with
siRNA targeting HTT mRNA (E1-4) significantly
lowered Huntingtin protein levels in the cultures by
50% compared to siRNA targeting GFP (Fig. 1b and
Supplementary Figure 1e; p < 0.01, n = 3). Huntingtin
lowering using siRNA E1-4 significantly increased
the basal level of Rac1, 2, 3 activation compared to
GFP siRNA (Fig. 1c; p < 0.005, n = 6, t-test). Western
blot analysis showed levels of Rac1 were similar with
siRNA E1-4 targeting HTT mRNA and siRNA GFP
mRNA (Supplementary Figure 1 g). PDGF treatment
of cells with reduced levels of Huntingtin rapidly
induced about a 50% detachment of cells during the
wash steps and precluded our ability to measure lev-
els of active Rac following PDGF stimulation. These
findings show that Huntingtin participates in the nor-
mal homeostasis of Rac activation.
Next, we looked for interactions between endoge-
nous Huntingtin and components of the PI 3-kinase/
Rac pathway using immunoprecipitation assay with
anti-Huntingtin antibody MAB2166. From lysates
of control human fibroblasts, negligible amounts of
p85 co-immunoprecipitated with Huntingtin; how-
ever, upon stimulation with PDGF detectible levels
of p85 co-precipitated with Huntingtin and were
significantly higher than without PDGF (Fig. 1d, e;
p < 0.05, n = 3 experiments), indicating a stimulus
dependent interaction. In HD fibroblasts, the levels
of p85 that co-immunoprecipitated with Huntingtin
after PDGF stimulation were not statistically signif-
icant compared to non-stimulated HD cells (Fig. 1d,
e). Pixel intensity quantification results of the input
lysates showed that PI 3-kinase p85 levels were
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Fig. 1. Rac (1, 2, 3) activation is altered in human HD fibroblasts and by loss of Huntingtin. (a) Bar graph shows mean ± SD of relative Rac
(1, 2, 3) activity (OD490) in primary human control and HD fibroblasts. CAG repeat length for both alleles is indicated under the x-axis.
PDGF treatment significantly increased relative Rac (1, 2, 3) activity in control fibroblasts but not in three HD cell lines (ANOVA and Tukey’s
HSD posthoc tests, F = 5.03, *p < 0.01, n = 6 technical replicates except HD17/69 –PDGF which is n = 4). (b) Huntingtin lowering by siRNA
(E1–4). Bar graph shows mean ± SD for Huntingtin pixel intensity quantification standardized to tubulin in control fibroblasts as percent of
mock by western blot (*p < 0.05, n = 3 biological replicates, unpaired t-test compared to GFP). Western blots are shown in Supplementary
Figure 1e. (c) Relative Rac (1, 2, 3) activity (OD490) was measured in lysates from cells transfected with HTT siRNA compared to GFP
siRNA. Bar graph shows mean ± SD of relative Rac (1, 2, 3) activity with siRNA for GFP or Huntingtin. In the Huntingtin (E1–4) treated
cells, there is a significant increase in the basal level of Rac (1, 2, 3) activation per microgram protein (*p < 0.005, n = 6 technical replicates,
paired t-test). (d) Huntingtin interacts with PI 3 kinase p85. Primary human fibroblasts were serum-starved for 48 h then stimulated with
PDGF added directly to the medium for 7 minutes (100 ng/ml final concentration). The CAG repeat length for each allele of the HD gene
is indicated in parenthesis at top. Anti-Huntingtin antibody MAB2166 was used to isolate Huntingtin from control and HD fibroblasts.
Control lanes are B (buffer alone with protein G and primary antibody), and no ab control (protein G incubated with input lysates without
primary antibody). Western blots probed with anti-Huntingtin Ab1 then re-probed with anti-p85 PI 3-kinase. -tubulin was used as a loading
control. Molecular mass markers are on the left. Black lines indicated where lanes were removed from the same gel. (e, f) Pixel intensity
quantification of immunoprecipitation (IP) results for p85 PI 3-kinase standardized to signal for Huntingtin (e) and inputs standardized to
-tubulin (f) shows a significant increase in level of p85 PI 3-kinase in Huntingtin-immunoprecipitates with PDGF treatment for control
fibroblasts but not HD fibroblasts and PI 3-kinase p85 levels were significantly reduced in HD cells compared to the normal control in the
inputs. Bar graph shows mean ratio ± SD, *p < 0.05, n = 3 experiments, unpaired t-test.
significantly reduced in HD cells compared to the
normal control (Fig. 1d, f). These results show
that endogenous Huntingtin associates with p85, a
major component of the receptor tyrosine kinase/PI3
kinase/Rac pathway. Polyglutamine expansion in
endogenous Huntingtin reduced the association and
stimulus dependent interaction with p85 in human
fibroblasts.
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Rac1 activity is altered in human HD NSCs and
neuron cultures, and mouse HD striatum and is
rescued by Huntingtin correction or lowering
Although HD affects peripheral cells, CNS cells
are severely affected and the hallmark of HD is
degeneration of cortical and striatal neurons. To deter-
mine if Rac activation was affected in more relevant
cell types, we examined human neural stem cells
(NSCs) derived from control or HD induced pluripo-
tent stem cells (IPSCs). The presence of wild-type
(WT) and mutant HTT (HD) alleles and protein were
confirmed by PCR and western blot (Supplementary
Figure 2a, b), as were levels of other markers of the
neural lineage. Nestin-positive cells were assessed
by immunofluorescence (Supplementary Figure 2c).
The cells were all heterozygous and the polyglu-
tamine lengths for the longest allele (including the
CAA following the CAG tract) were 17Q for WT54,
33Q for WT97; 51Q for HD51, 42Q for HD48, 72Q
for HD4, 21Q for HDc116. These experiments were
performed using an ELISA specific for Rac1 and with
a luminescent readout. Unlike fibroblasts, control
NSCs did not respond to PDGF but instead responded
to BDNF by significantly increasing their levels of
active Rac1 (Fig. 2a). BDNF is a growth factor that
also activates the PI 3-kinase pathway and can reg-
ulate morphology changes in neural cell types. HD
NSCs had elevated basal levels of Rac1 activation that
were equal to or higher than the BDNF-stimulated
levels of the control NSCs (Fig. 2a). Treatment with
BDNF failed to significantly increase Rac1 activation
further in any of the HD lines tested suggesting that
the HD cells were maximally stimulated in basal con-
ditions. Crucially, an isogenic line (HDc116 NSCs) to
HD4 in which the repeat was reduced to 21 CAGs via
homologous recombination [51] had basal Rac1 acti-
vation levels that were significantly lower compared
to HD4 (Fig. 2b).
Rac1 activation was also measured in human
control WT and HD neuron cultures that were dif-
ferentiated from IPSC using the method described
by Arber et al. [40]. Neuronal cultures were char-
acterized for the presence of normal and mutant
Huntingtin and for neuronal phenotypes using west-
ern blot and immunofluorescence (Supplementary
Figure 2d, e). Like the HD NSCs, HD51 neuron
cultures (51Q) had increased levels of basal active
Rac1 compared to WT97 neurons (Fig. 2c) and
compared to WT54 (Supplementary Figure 3a). Low-
ering Huntingtin in human WT97 neuron cultures
with a chemically modified siRNA called HTT10150
targeting HTT mRNA significantly increased the lev-
els of Rac1 activity compared to cultures treated
with a non-targeting (NTC) control siRNA with the
same chemical modification, indicating that Hunt-
ingtin in neuron cultures is normally required for
the maintenance of Rac1 homeostasis (Fig. 2d, f;
Supplementary Figure 3b). In HD51 neuron cultures,
lowering Huntingtin (both normal and mutant alleles)
attenuated the elevated levels of Rac1 activity to that
of WT97 cells treated with the control siRNA (NTC
treated group) (Fig. 2e, g; Supplementary Figure 3b).
These results suggest that reducing total Huntingtin in
the presence of the HD mutation can restore normal
levels of Rac activity. Using independent neuronal
cultures and siRNA HTT10150 to lower Huntingtin
protein levels, the same results were found using the
ELISA assay for Rac1, 2, 3 activity (Supplementary
Figure 3c, d-g). The magnitude of change was slightly
higher using the Rac1, 2, 3 assay possibly due to dif-
ferences in the enzymatic readout between the assays
or a contribution of Rac3 (see Discussion).
Finally, we examined levels of Rac1 activation in
a mouse model of HD. Primary embryonic cortical
neurons from knock-in Q140/Q140 HD mice had
increased basal levels of Rac1, 2, 3 activity compared
to WT neurons at 5, 7 and 11 days in vitro (Fig. 3a,
published previously in [52]). Relative Rac1 activity
was examined in the striatum and cortex of the WT
and knock-in Q140/Q140 HD mice at 1.5 and 4.5
months. Compared to the striatum of WT mice, the
striatum of Q140/Q140 HD mice had increased levels
of Rac1 activation at 1.5 months (Fig. 3b). However,
by 4.5 months, the level of Rac1 activity in HD stria-
tum was significantly lower than in WT. Rac1 activity
in striatum and cortex of WT mice increased sig-
nificantly with age. Rac1 activity in the cortex was
not different between WT and HD mice at the ages
examined (Fig. 3b).
To ascertain if an increase in levels of Rac1 pro-
tein could explain the increases in Rac1 activation
in NSCs and neurons, we detected Rac1 protein by
western blot assay. No consistent change in levels
of Rac1 protein was observed between WT and HD
human NSCs or human neuron cultures (Supplemen-
tary Figure 2b, d). HD48 NSCs did have a higher
level of Rac1 protein compared to the other NSCs,
but both HD51 and HD4 had similar levels to WT
NSCs. However, Rac1 protein levels were signifi-
cantly lower at 1.5 months in striatum of Q140/Q140
HD mice compared to WT mice (Fig. 3c, middle row
and bar graph). The levels of two surface receptors
that can activate Rac1, p75NTR and the BDNF recep-
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Fig. 2. Rac1 activity in human NSCs and neurons and effects of Huntingtin lowering. (a) Bar graph shows mean ± SD of relative Rac1
activity (Luminescence RLUx106) for human control NSCs (WT54 and WT97) and HD NSCs (HD48, HD51, and HD4), without and with
BDNF treatment. In WT cells Rac1 activity is increased with BDNF treatment as expected compared to unstimulated WT cells (ANOVA and
Tukey’s HSD posthoc tests *p < 0.01; n = 3 technical replicates). In non-stimulated conditions (–BDNF), relative Rac1 activity is increased
in HD NSCs compared to WT NSCs (+p < 0.01). (b) Graph shows mean ± SE of relative Rac1 activity (Luminescence RLU × 106) in
NSCs from line HD116c (genetically corrected HD4 line) and HD4. Genetic correction significantly decreases relative Rac activity levels
(*p < 0.01, n = 12 wells from 3 biological replicates, unpaired t-test). (c) Basal Rac1 activity in human HD (HD51) neurons is increased
compared to WT (WT54) neurons. Graph shows mean ± SD of relative Rac1 activity at DIV35 (*p < 0.05, unpaired t-test, n = 4 technical
replicates). (d-g) Lowering Huntingtin increases Rac1 activity in WT neurons and reduces Rac1 activity to normal levels in HD neurons.
WT97 and HD51 were treated with siRNA HTT10150 targeting HTT mRNA or with a non-targeting control (NTC) and harvested for
Huntingtin detection by western blot with antibody directed to htt1–17 (Ab1) (d and e) and for Rac1 activity (f and g). Bar graphs show
results for mean Huntingtin signal intensity based on pixel intensity quantification as percent of untreated control and relative Rac1 activity in
siRNA HTT10150 (HTT) treated and non-targeting control (NTC) treated cells (*p < 0.05, ANOVA with Bonferroni’s Multiple Comparison
test, n = 3 technical replicates). Black line in f and g shows Rac1 levels in the untreated cells measured on the same ELISA plate.
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Fig. 3. Rac1, 2, 3 and Rac1 activity in WT and HD mouse primary neurons, striatum and cortex. (a) Primary embryonic cortical neurons
from knock-in Q140/Q140 HD mice have increased basal levels of Rac1, 2, 3 activity compared to WT neurons (*p < 0.01, unpaired t-test,
n = 3–4). Reported before in a previous paper retracted for problems with other data. (b) Basal Rac1 activity in the striatum and cortex of WT
and Q140/Q140 HD mice. Graphs show mean relative Rac1 activity ± SD (ANOVA and Tukey’s HSD posthoc tests, F = 20.36 in “striatum”
and 27.32 in “cortex”; *p < 0.001 **p < 0.05, n = 4 mice per genotype at 1.5 months and 4.5 months). In the striatum, relative Rac1 activity
is increased in HD compared to WT at 1.5 months, but decreased at 4.5 months. In the cortex relative Rac1 activation is increased in WT
and HD mice at 4.5 months compared to 1.5 months. (c) Western blot analysis of lysates from striatum of WT and HD mice at 1.5 and
4.5 months. Top blots probed with antibody to Huntingtin to verify genotype (10g protein separated on 3–8% Tris-acetate SDS-PAGE).
Middle and bottom blots probed with antibody to Rac1 and re-probed with antibody to GAPDH as a loading control (10g protein separated
on 4–12% Bis-tris SDS-PAGE). Space indicates separate gels. Pixel intensity quantification results at right show less Rac1 protein in HD
mice at 1.5 months. Bars are mean ± SD, *indicates p < 0.05, n = 4 mice, unpaired t-test.
tor TRKB, also were not different between WT and
HD mice in 1.5-month cortex and striatum; however,
a significant reduction in TRKB protein was appar-
ent in striatum at 4.5 months in HD compared to WT
(Supplementary Figure 4a, b). Finally, we did not
observe any changes in levels of the GEFs for Rac1,
Kalirin-7 or Kalirin-8, in striatum of Q140/Q140 HD
mice (Supplementary Figure 4b) that might explain
increased Rac1 activation.
Collectively, the results show that PI 3-kinase-
dependent Rac1 activation is impaired by the
presence of mutant Huntingtin in HD human NSCs
and neuron cultures, primary embryonic cortical neu-
rons of HD mice, and in the striatum of young HD
mice. Furthermore, correction of the HD mutation
by homologous recombination in human NSCs or by
lowering overall levels of Huntingtin in human HD
neuron cultures reduced basal Rac1 activity to nor-
mal levels. The elevated levels of Rac1 activation in
HD cannot be explained by increased Rac1 protein
or changes in upstream receptors tyrosine kinases,
p75NTR or TRKB, or in levels of Kalirin-7 or
Kalirin-8.
Huntingtin is in a complex with Rac1, p85α
subunit of PI 3-kinase, and alpha-actinin in brain
To look for interactions between endogenous
Huntingtin and components of the PI 3-kinase/Rac
pathway in brain, we performed immunoprecipita-
tions from WT and HD Q140/Q140 mice total brain
lysates using anti-Huntingtin MAB2166 and a rapid
immunoprecipitation protocol (see Methods). Con-
sistent with previous findings in PC12 cells [9, 16]
and in human fibroblasts (this study, Fig. 1d, e),
the p85 regulatory subunit of PI 3-kinase (p85)
was detected in anti-Huntingtin immunoprecipitates
(Fig. 4). In contrast to results found in human fibrob-
lasts (this study, Fig. 1), no significant difference in
the levels of pull down for either protein occurred
between wild-type and Q140/Q140 HD mice (n = 4
experiments; unpaired t-test). These same Huntingtin
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Fig. 4. Rac and p85 PI 3-kinase both co-immunoprecipitate with
endogenous Huntingtin. (a) Western blot analysis of Huntingtin
(Htt) immunoprecipitated from wild-type (WT) and Q140/Q140
(HD) adult mouse brain using anti-Huntingtin antibody MAB2166.
Eluates were analyzed using two gel formats. Blot from a 3–8%
SDS-PAGE gel was probed with polyclonal anti-Huntingtin Ab1
to confirm presence of full-length Huntingtin (∼350 kDa) (top).
Blot from 4–12% SDS-PAGE gel was probed for p85 regulatory
subunit of PI 3-kinase (middle blot, arrow) and Rac1 (bottom blot,
arrow). The mouse IgG light chains (indicated) are recognized by
the secondary antibody on the Rac1 probe. Vertical lines indicate
where lanes were removed from same gel.
immunoprecipitates from WT and HD mouse brains
also contained Rac1 (Fig. 4). We were unable to
find conditions allowing for immunoprecipitation
of endogenous Huntingtin with Rac1 using a Rac1
antibody. To gain more information regarding the reg-
ulation of the interaction of Rac1 and Huntingtin,
we performed affinity chromatography using bac-
terially expressed GST-Rac1 fusion protein loaded
with GTPS (the active state of Rac1) or loaded
with GDP (the inactive state of Rac1) and lysates
from dissected striatum from WT or Q140/Q140 HD
mouse brains at 1.5 months (Fig. 5a-d). Western blots
showed WT Huntingtin and mutant Huntingtin were
eluted in the first fraction and preferentially pulled
down with GST-Rac1[GTPS] compared to GST-
Rac1[GDP] (Fig. 5a, b, lanes E1 GTP and E1 GDP).
Similarly, PI 3-kinase p85 pulled down with GST-
Rac1[GTPS] from both WT and HD lysates and
co-eluted with Huntingtin (Fig. 5a, b). Silver stained
gels of starting fraction (S1), flow-through (FT) frac-
tions and eluates (E) of the same experiment are
shown in Fig. 5c and d. Western blots from a con-
trol reaction using GST alone showed no detectible
Huntingtin or PI 3-kinase pulled down (Fig. 5e, lanes
E1 GTP and E1 GDP). A silver stained gel from
the GST only column with WT mouse striatum S1
input also shows many fewer proteins eluting from
the column (Fig. 5f). These results show that as in
human fibroblasts (Fig. 1), endogenous Huntingtin
in striatum associates with components of the recep-
tor tyrosine kinase/PI3 kinase/Rac pathway (Rac1
and p85) and that Huntingtin and PI 3-kinase p85
associate preferentially with the GTP bound state of
Rac1.
-actinin-1 and Rac1 work together in the assem-
bly of stress fibers during cell spreading and cell
migration [53] and Rac1 promotes assembly of
vinculin and -actinin containing complexes [47].
Previous work by others suggested that Huntingtin
might interact with -actinin isoforms [18, 23, 24].
We found that -actinin-2 which is enriched in
striatum was pulled down with GST-Rac1 affinity
chromatography using striatal lysates in the same
fraction as Huntingtin (Fig. 5a, b, lanes E1 GTP and
E1 GDP), suggesting that -actinin-2, Rac1, PI 3-
kinase and Huntingtin may co-exist in a complex
in brain. A control experiment using lysates from
WT striatum and GST alone did show some back-
ground binding of -actinin-2, but the signal for
GST-Rac1 was higher using the same mass protein
input (Fig. 5e).
DISCUSSION
The preferential interactions of native Huntingtin
with the lipid products of PI 3-kinase, PI(3,4)P2 and
PI(3,4,5)P3, led us to examine the role of Huntingtin
in the activity of Rac1 which is a downstream tar-
get of receptor tyrosine kinase/PI-3 kinase dependent
signaling that regulates changes in morphology in
response to growth factors. In this study, we demon-
strated that endogenous Huntingtin interacts with
endogenous Rac1, the p85 subunit of PI 3-kinase
and may associate with -actinin-2 in a protein com-
plex. Acute reduction of Huntingtin increased basal
Rac1 activity in human control fibroblasts and neu-
ronal cultures, and the presence of mutant Huntingtin
increased basal Rac1 activity and impaired growth
factor dependent activation of Rac1. The increase in
basal Rac1 activity occurred in HD cells of neuroec-
todermal origin (neural stem cells/glia and neurons)
which could be a factor in HD pathogenesis in the
CNS. Rac1 is ubiquitously expressed whereas Rac2 is
restricted to T-, B- and hemopoietic cell lineages [20,
21]. Rac3 transcripts are expressed most prominently
in brain tissue but also in heart, pancreas and placenta
[22]. Here, Rac activation levels were measured using
both an assay for Rac1, 2, 3 as well as one more spe-
cific to Rac1 in human neuron cultures and found to be
changed in the same direction with both assays. These
results show that Rac1 activity contributes in part
to altered Rac activity in human neurons. However,
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Fig. 5. Affinity chromatography isolates a protein complex with GST-Rac1[GTPS] including Huntingtin, p85, and -actinin-2. Affinity
chromatography using GST-Rac1[GSTS] or GST-Rac1[GDP] with lysates from wild-type (WT) or HD (Q140/Q140) mouse striatum at
1.5 months. Lanes (applies for a-f): P1, 2000 g pellet fraction; S1, 2000 g supernatant which was used as input for column; FT GTP and FT
GDP, flow-through fractions; GTP E1–E5, elutions 1–5 from GST-Rac1[GSTS] column. GDP E1–E5, elutions 1–5 from GST-Rac1[GDP]
column; lanes at far right loaded with pure GST-Rac1 protein at indicated concentrations to identify fusion protein on the gels. (a, b) Western
blots of fractions indicated at top of blots were probed for Huntingtin (Htt) with Ab1 targeting aa1–17 of Huntingtin, -actinin-2, PI 3-kinase
p85 regulatory subunit, and for Rac1 as indicated at right of blots. Relative molecular mass is indicated in kilodalton at left. Black lines
indicate removal of marker lanes from samples that were run on the same gel exactly as in c and d. (c, d) Silver stained gels of the same
samples shown in a and b. Molecular weight markers indicated on left or within gel lane at left. Marker 1 (EZ Run), Marker 2 (SeeBlue).
Silver stains were overdeveloped to visualize high molecular weight proteins (Huntingtin). (e, f) Western blot and silver stained gel of affinity
chromatography input, flow through and elutions using GST alone with lysates from wild-type (WT) mouse striatum at 1.5 months as a
control. Low background binding was observed with -actinin-2, but binding to GST-Rac1 was significantly higher. Vertical lines in a,b,
and e indicate where lanes were removed from the same gel.
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since Rac3 is highly expressed in brain and a greater
change was observed when measuring Rac1, 2, 3
activity, we cannot exclude contributions from Rac3
in NSCs and neurons and mouse brain. The Rac activ-
ity measured in fibroblasts using the Rac 1, 2, 3
method was likely arising from Rac1 since Rac2 and
3 have restricted expression patterns. A large scale
proteomic study with GST-Huntingtin fragments and
mouse brain lysates identified Rac1 as an interactor
(Rac 2 and Rac 3 were not identified) [17] supporting
the idea that Huntingtin regulates Rac1.
Our findings here together with work on the roles
of Rac1 and -actinin in other studies [53–55] sug-
gest that Huntingtin regulates Rac activity as part
of a coordinated response to growth factor signal-
ing. A logical scenario is that upon growth factor
stimulation, Huntingtin associates with p85 PI 3-
kinase. PI(3,4,5)P3, which is created on the plasma
membrane by the PI 3-kinase complex (regulatory
plus catalytic domains) [56], causes dissociation of
-actinin from beta-integrin in adhesion plaques to
allow restructuring of the plaques, as previously
described [54]. Huntingtin then could act as a scaf-
fold to support p85 PI 3-kinase, -actinin and Rac1
at new focal regions on membranes for localized acti-
vation of Rac1 and the WAVE regulatory complex for
Arp2/3 nucleation of actin polymerization [50, 57].
Using brain lysates, we found -actinin-2 retained
on a GST-Rac1 column together with Huntingtin and
p85. In neurons, the shape of spines is regulated by
both -actinin-2 [31] and Rac activity (see below).
Our finding that reducing Huntingtin levels increased
Rac1 activation, suggests that Huntingtin may also
coordinate complexes to curtail Rac1 activation, per-
haps through its interaction with p85. p85 has been
implicated in negative feedback regulation of Rac1
[58] and directly interacts with Huntingtin by yeast
two-hybrid assay [17, 18]. Alternatively, Huntingtin
may coordinate a guanine nucleotide exchange factor
(GEF) or GTPase activating protein (GAP) activi-
ties to control Rac activation levels. Interactome data
[18, 23, 24, 59] suggests that Huntingtin associates or
interacts with numerous GAPs including ARHGAP
21, ARHGAP 23, ARHGAP 24, and ARHGAP 25,
and SRGAP1–3. That Huntingtin in brain preferen-
tially associates with Rac1 in its GTP bound state
is most consistent with the idea that Huntingtin
coordinates negative regulation through recruitment
of a GAP or via PI 3-kinase p85. Future exper-
iments will be aimed at defining which molecules
Huntingtin coordinates to achieve normal regulation
of Rac1.
Basal levels of Rac1 activity were elevated com-
pared to WT in human HD NSCs and neurons,
HD mouse primary cortical neurons, and striatum
of 1.5-month-old HD mice. In HD cells (human
HD fibroblasts and human HD NSCs), growth fac-
tor stimulation failed to increase Rac activity but
likely through different mechanisms since the rest-
ing level of Rac1, 2, 3 activity was normal in HD
fibroblasts but elevated in HD NSCs compared to con-
trols. The lack of Rac1, 2, 3 activation in response
to stimulation in human HD fibroblasts is consis-
tent with previous findings showing impaired ruffling
response of peripheral HD monocytes to stimulation
[60]. Our results suggest that the mechanism under-
lying these Rac1 signaling alterations are different
between peripheral (fibroblasts and monocytes) and
central nervous system cells (neural-derived cells).
In fibroblasts, one possibility is that mutant Hunt-
ingtin has direct effects on PI 3-kinase activity. We
found that HD fibroblasts had lower levels of PI 3-
kinase p85 than control fibroblasts in total lysates
and in co-precipitates with Huntingtin which could
prevent full activation of Rac by the complex that
contains Huntingtin. On the other hand, normal and
mutant Huntingtin from mouse brain pulled down
similar amounts of p85, and yeast two hybrid studies
have shown no change in interaction of p85 subunits
with polyglutamine expansion in Huntingtin frag-
ments [18]. Two HD fibroblasts lines also had trends
for lower levels of Rac1 protein. Although basal lev-
els of Rac1, 2, 3 activity were not changed compared
to the control line, lower levels of total Rac1 protein
may reduce the amount of Rac1 present at the correct
location available for further activation with growth
factor stimulation. Other factors may contribute to
excessive Rac1 activity in HD neural cells such as
inappropriate activation via GEFs, a reduced capac-
ity to attenuate Rac activation via GAPs, or a failure
to remove Rac1 from the membrane via the protein
Rho GDi. The divergent response between peripheral
cells and CNS cells also might be due to stimulation
using different growth factors (PDGF in fibroblasts
versus BDNF in NSCs).
We recently described an interaction with Hunt-
ingtin and Kalirin-7, a known GEF for Rac1 [61].
Our in vitro studies suggested that mutant Hunt-
ingtin can inhibit exchange of GTP onto GST-Rac1
facilitated by Kalirin-7. One would predict then
that cells expressing mutant Huntingtin should have
lower Rac1 activation, as observed in fibroblasts
but not cells of neural ectoderm origin. It is pos-
sible that another GEF is upregulated in early
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developing HD neuroectodermal cells resulting in
over-compensation. After the early increased activa-
tion of Rac1 in HD knock-in mice, we did observe
a significant decrease in Rac activation. This is con-
sistent with results by Puigdellı´vol et al. (2105) who
found decreased Rac1 activation in cortex at 8 months
in Q111/Q7 HD mice paralleling changes in number
of synapses [62]. Gines and colleagues attributed the
activation in Rac1 to decreased levels of Kalirin-7
at 8 months, which we did not observe in striatum
of Q140/Q140 HD mice at 4.5 months. The same
group also described an increased RhoA activation
due to upregulation of p75NTR [63, 64]. We did not
see differences in levels of p75NTR at 1.5 months in
striatum when Rac1 activation levels were elevated in
Q140/Q140 HD mice. We did see a small reduction in
the BDNF receptor, TRKB, at 4.5 months when Rac1
activity was reduced. Thus, our results are consistent
with the idea that decreased Rac1 activation levels at
later ages may be due to an imbalance in signaling
between p75NTR and TRKB. However, since Rac1
activation is elevated early in HD mice or in cells
at developmental stages (NSCs or embryonic neu-
rons), our results suggest an early imbalance in small
GTPase activities. Altogether, findings point to ongo-
ing disruption of the Rac pathway starting early with
increased activity that could be either compensatory
or a primary site of pathology followed by eventual
degradation of Rac signalling capacity with age and
disease progression.
Elevated basal Rac1 activity in HD neurons may
have effects on neuronal development and/or sur-
vival in the disease. Tourette et al. showed that
reducing Rac1 levels with siRNA in immortalized
striatal mouse cells from HD mice (HdhQ111/Q111)
reduced levels of active Caspase 3/7, demonstrat-
ing a neuroprotective effect [18] and suggesting
increased Rac1 activation is not compensatory but
pathogenic. In normal mouse brain, Rac activity and
regulation by one of its GEFs, Kalirin7, are criti-
cal for neuronal development, dendritic arborization
and spine morphogenesis in neurons [65–70]. Mouse
neurons expressing constitutively active Rac in vivo
displayed altered dendritic spine morphologies [71]
reminiscent to those previously described in HD
patient brains. McKinstry and colleagues showed an
increased number of mature spines at 21 days in the
dorsal striatum at the expense of intermediate spines
in heterozygous KI HD mouse model, zQ175; how-
ever, by 5 weeks the total spine density was lower
in the zQ175 dorsal striatum compared to WT with
a reduction in mature spines, suggesting a dynamic
process of dendrite morphology changes and a devel-
opmental component [72]. These findings are in line
with ours in that increased Rac1 activation in stria-
tum occurred early at 1.5 months then was lower at
4.5 months in homozygous Q140/Q140 HD brains.
Our data suggest intrinsic excess Rac1 activation
is a proximal event in HD and maybe the molecu-
lar mechanism underlying dendritic spine changes.
We speculate that the reduction in Rac1 activation
observed in older Q140/Q140 HD mice is either a
compensatory response to the increased activation
measured in young animals or an early indication of
degeneration and loss of synaptic terminals. In human
striatum and cortex from HD patient autopsy tissue,
both increases and decreases in dendritic outgrowth
and spine density of medium spiny neurons (MSNs)
and cortical neurons have been reported using the
Golgi-Cox method [73–75]. Although autopsy find-
ings provide only a snapshot of ongoing disease
process, even at death HD brains show a spectrum
of cells undergoing regenerative and degenerative
states.
WT and HD neuronal cultures responded in a
profoundly different manner to lowering of total
Huntingtin protein. In human control fibroblasts and
neuron cultures, cells responded to lowered normal
Huntingtin by increasing Rac1 activation. One inter-
pretation of this response is that Huntingtin helps to
negatively regulate of Rac1 activity. Another possi-
bility is that Rac1 activation is an indirect effect from
some other change produced in the cell by Huntingtin
lowering. In contrast, lowering total Huntingtin levels
(both normal and mutant Huntingtin) in HD neuronal
cultures appeared to correct an aberrant increase in
Rac1 activation. This finding shows that the homeo-
static set point for WT and HD cells is very different.
This is not surprising since transcriptional changes
can be found even at the IPSC [51] and NSC stage [76]
suggesting either a pathological problem or an adap-
tation to the presence of mutant Huntingtin early on in
development. Our data support the notion that ongo-
ing trials using Huntingtin lowering reagents may
be beneficial to HD patients, but the same treatment
might be quite toxic to a normal individual.
Conclusions
Our data support a role for Huntingtin in modulat-
ing Rac1 activity which occurs in response to growth
factor signaling and is important for actin cytoskele-
tal reorganization at membranes. Changes in Rac1
activity occur early in the HD brain and could reg-
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ulate plasticity of developing neurons and dendritic
spines and contribute to the abnormalities in dendrite
growth and spine density of medium spiny neurons
described in the HD postmortem brain [74].
ACKNOWLEDGMENTS
This work was supported by a contract from CHDI,
Inc. to KKG and MD and the Dake Family Fund to
MD and KKG. We are grateful for help with confocal
microscopy from Yun Joon Kim and Luke Maynard.
KKG spouse owns less than 0.1% stock in
the following companies: Bristol-Myers Squibb
Company, Cisco Systems, Inc., GE Healthcare
Life Sciences, Generex Biotechnology Corporation,
GlaxoSmithKline, Metabolix Bioplastics, Nanogen,
Inc., Nanometrics, inc., StemCells, Inc.
CONFLICT OF INTEREST
All purchases are compliant with Research
Procurement standards that both individual and
organizational conflicts of interest compliance with
Uniform Guidance (UG) Procurement Standards
issued by the Office of Management and Budget
(OMB). No other authors have conflicts of interest
to report.
SUPPLEMENTARY MATERIAL
The supplementary material is available in the
electronic version of this article: http://dx.doi.org/
10.3233/JHD-180311.
REFERENCES
[1] A novel gene containing a trinucleotide repeat that is
expanded and unstable on Huntington’s disease chromo-
somes. The Huntington’s Disease Collaborative Research
Group. Cell. 1993;72(6):971-83.
[2] Duyao MP, Auerbach AB, Ryan A, Persichetti F, Barnes GT,
McNeil SM, et al. Inactivation of the mouse Huntington’s
disease gene homolog Hdh. Science. 1995;269(5222):407-
10.
[3] Nasir J, Floresco SB, O’Kusky JR, Diewert VM, Richman
JM, Zeisler J, et al. Targeted disruption of the Huntington’s
disease gene results in embryonic lethality and behav-
ioral and morphological changes in heterozygotes. Cell.
1995;81(5):811-23.
[4] Zeitlin S, Liu JP, Chapman DL, Papaioannou VE, Efstra-
tiadis A. Increased apoptosis and early embryonic lethality
in mice nullizygous for the Huntington’s disease gene homo-
logue. Nat Genet. 1995;11(2):155-63.
[5] Harjes P, Wanker EE. The hunt for huntingtin function:
Interaction partners tell many different stories. Trends
Biochem Sci. 2003;28(8):425-33.
[6] Saudou F, Humbert S. The biology of Huntingtin. Neuron.
2016;89(5):910-26.
[7] O’Kusky JR, Nasir J, Cicchetti F, Parent A, Hayden MR.
Neuronal degeneration in the basal ganglia and loss of
pallido-subthalamic synapses in mice with targeted dis-
ruption of the Huntington’s disease gene. Brain Res.
1999;818(2):468-79.
[8] Dragatsis I, Levine MS, Zeitlin S. Inactivation of Hdh in the
brain and testis results in progressive neurodegeneration and
sterility in mice. Nat Genet. 2000;26(3):300-6.
[9] Song C, Perides G, Liu YF. Expression of full-length
polyglutamine-expanded Huntingtin disrupts growth factor
receptor signaling in rat pheochromocytoma (PC12) cells.
J Biol Chem. 2002;277(8):6703-7.
[10] Kegel KB, Sapp E, Alexander J, Valencia A, Reeves
P, Li X, et al. Polyglutamine expansion in huntingtin
alters its interaction with phospholipids. J Neurochem.
2009;110(5):1585-97.
[11] Kegel KB, Sapp E, Yoder J, Cuiffo B, Sobin L, Kim YJ,
et al. Huntingtin associates with acidic phospholipids at the
plasma membrane. J Biol Chem. 2005;280(43):36464-73.
[12] Schlessinger J. Cell signaling by receptor tyrosine kinases.
Cell. 2000;103(2):211-25.
[13] Vanhaesebroeck B, Waterfield MD. Signaling by dis-
tinct classes of phosphoinositide 3-kinases. Exp Cell Res.
1999;253(1):239-54.
[14] Nobes CD, Hawkins P, Stephens L, Hall A. Activation of
the small GTP-binding proteins rho and rac by growth factor
receptors. J Cell Sci. 1995;108(Pt 1):225-33.
[15] Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM,
Pappin D, Das P, et al. Role of phosphoinositide 3-OH kinase
in cell transformation and control of the actin cytoskeleton
by Ras. Cell. 1997;89(3):457-67.
[16] Liu YF, Deth RC, Devys D. SH3 domain-dependent asso-
ciation of huntingtin with epidermal growth factor receptor
signaling complexes. J Biol Chem. 1997;272(13):8121-4.
[17] Kaltenbach LS, Romero E, Becklin RR, Chettier R, Bell
R, Phansalkar A, et al. Huntingtin interacting proteins
are genetic modifiers of neurodegeneration. PLoS Genet.
2007;3(5):e82.
[18] Tourette C, Li B, Bell R, O’Hare S, Kaltenbach LS,
Mooney SD, et al. A large scale Huntingtin protein
interaction network implicates Rho GTPase signaling path-
ways in Huntington disease. J Biol Chem. 2014;289(10):
6709-26.
[19] Burridge K, Wennerberg K. Rho and Rac take center stage.
Cell. 2004;116(2):167-79.
[20] Moll J, Sansig G, Fattori E, van der Putten H. The murine
rac1 gene: cDNA cloning, tissue distribution and regulated
expression of rac1 mRNA by disassembly of actin microfil-
aments. Oncogene. 1991;6(5):863-6.
[21] Shirsat NV, Pignolo RJ, Kreider BL, Rovera G. A member of
the ras gene superfamily is expressed specifically in T, B and
myeloid hemopoietic cells. Oncogene. 1990;5(5):769-72.
[22] Haataja L, Groffen J, Heisterkamp N. Characterization of
RAC3, a novel member of the Rho family. J Biol Chem.
1997;272(33):20384-8.
[23] Culver BP, Savas JN, Park SK, Choi JH, Zheng S, Zeitlin
SO, et al. Proteomic analysis of wild-type and mutant
huntingtin-associated proteins in mouse brains identifies
unique interactions and involvement in protein synthesis.
J Biol Chem. 2014;287(26):21599-614.
68 A. Tousley et al. / Huntingtin Modulates Rac1 Activity
[24] Shirasaki DI, Greiner ER, Al-Ramahi I, Gray M, Boon-
theung P, Geschwind DH, et al. Network organization of
the huntingtin proteomic interactome in mammalian brain.
Neuron. 2012;75(1):41-57.
[25] Angeli S, Shao J, Diamond MI. F-actin binding regions
on the androgen receptor and huntingtin increase aggre-
gation and alter aggregate characteristics. PLoS One.
2010;5(2):e9053.
[26] Munsie L, Caron N, Atwal RS, Marsden I, Wild EJ, Bam-
burg JR, et al. Mutant huntingtin causes defective actin
remodeling during stress: Defining a new role for transglu-
taminase 2 in neurodegenerative disease. Hum Mol Genet.
2011;20(10):1937-51.
[27] Shao J, Welch WJ, Diprospero NA, Diamond MI. Phos-
phorylation of profilin by ROCK1 regulates polyglutamine
aggregation. Mol Cell Biol. 2008;28(17):5196-208.
[28] Miller JP, Yates BE, Al-Ramahi I, Berman AE, Sanhueza
M, Kim E, et al. A genome-scale RNA-interference screen
identifies RRAS signaling as a pathologic feature of Hunt-
ington’s disease. PLoS Genet. 2012;8(11):e1003042.
[29] Djinovic-Carugo K, Young P, Gautel M, Saraste M.
Structure of the alpha-actinin rod: Molecular basis for cross-
linking of actin filaments. Cell. 1999;98(4):537-46.
[30] Sjoblom B, Salmazo A, Djinovic-Carugo K. Alpha-
actinin structure and regulation. Cell Mol Life Sci.
2008;65(17):2688-701.
[31] Hodges JL, Vilchez SM, Asmussen H, Whitmore LA, Hor-
witz AR. alpha-Actinin-2 mediates spine morphology and
assembly of the post-synaptic density in hippocampal neu-
rons. PLoS One. 2014;9(7):e101770.
[32] Menalled LB, Sison JD, Wu Y, Olivieri M, Li XJ, Li H,
et al. Early motor dysfunction and striosomal distribution of
huntingtin microaggregates in Huntington’s disease knock-
in mice. J Neurosci. 2002;22(18):8266-76.
[33] Valencia A, Reeves PB, Sapp E, Li X, Alexander J, Kegel
KB, et al. Mutant huntingtin and glycogen synthase kinase
3-beta accumulate in neuronal lipid rafts of a presymp-
tomatic knock-in mouse model of Huntington’s disease.
J Neurosci Res. 2010;88(1):179-90.
[34] Valencia A, Sapp E, Reeves PB, Alexander J, Masso N, Li
X, et al. Reagents that block neuronal death from Hunt-
ington’s disease also curb oxidative stress. Neuroreport.
2012;23(1):10-5.
[35] Kegel KB, Sapp E, Alexander J, Reeves P, Bleckmann D,
Sobin L, et al. Huntingtin cleavage product A forms in neu-
rons and is reduced by gamma-secretase inhibitors. Mol
Neurodegener. 2010;5:58.
[36] DiFiglia M, Sena-Esteves M, Chase K, Sapp E, Pfister E,
Sass M, et al. Therapeutic silencing of mutant huntingtin
with siRNA attenuates striatal and cortical neuropathol-
ogy and behavioral deficits. Proc Natl Acad Sci U S A.
2007;104(43):17204-9.
[37] Ritch JJ, Valencia A, Alexander J, Sapp E, Gatune L, San-
grey GR, et al. Multiple phenotypes in Huntington disease
mouse neural stem cells. Mol Cell Neurosci. 2012;50(1):70-
81.
[38] Ebert AD, Shelley BC, Hurley AM, Onorati M, Castiglioni
V, Patitucci TN, et al. EZ spheres: A stable and expandable
culture system for the generation of pre-rosette multipotent
stem cells from human ESCs and iPSCs. Stem Cell Res.
2013;10(3):417-27.
[39] Conti L, Pollard SM, Gorba T, Reitano E, Toselli M, Biella
G, et al. Niche-independent symmetrical self-renewal of a
mammalian tissue stem cell. PLoS Biol. 2005;3(9): e283.
[40] Arber C, Precious SV, Cambray S, Risner-Janiczek JR,
Kelly C, Noakes Z, et al. Activin A directs striatal projec-
tion neuron differentiation of human pluripotent stem cells.
Development. 2015;142(7):1375-86.
[41] Alterman JF, Hall LM, Coles AH, Hassler MR, Didiot MC,
Chase K, et al. Hydrophobically modified siRNAs silence
huntingtin mrna in primary neurons and mouse brain. Mol
Ther Nucleic Acids. 2015;4:e266.
[42] DiFiglia M, Sapp E, Chase K, Schwarz C, Meloni A, Young
C, et al. Huntingtin is a cytoplasmic protein associated
with vesicles in human and rat brain neurons. Neuron.
1995;14(5):1075-81.
[43] Benard V, Bohl BP, Bokoch GM. Characterization of rac
and cdc42 activation in chemoattractant-stimulated human
neutrophils using a novel assay for active GTPases. J Biol
Chem. 1999;274(19):13198-204.
[44] Hall DD, Dai S, Tseng PY, Malik Z, Nguyen M, Matt
L, et al. Competition between alpha-actinin and Ca(2)(+)-
calmodulin controls surface retention of the L-type Ca(2)(+)
channel Ca(V)1.2. Neuron. 2013;78(3):483-97.
[45] Scherzinger E, Lurz R, Turmaine M, Mangiarini L,
Hollenbach B, Hasenbank R, et al. Huntingtin-encoded
polyglutamine expansions form amyloid-like protein aggre-
gates in vitro and in vivo. Cell. 1997;90(3): 549-58.
[46] Christoforidis S, McBride HM, Burgoyne RD, Zerial M.
The Rab5 effector EEA1 is a core component of endosome
docking. Nature. 1999;397(6720):621-5.
[47] Martinez JJ, Hultgren SJ. Requirement of Rho-family
GTPases in the invasion of Type 1-piliated uropathogenic
Escherichia coli. Cell Microbiol. 2002;4(1):19-28.
[48] Miki H, Suetsugu S, Takenawa T. WAVE, a novel WASP-
family protein involved in actin reorganization induced by
Rac. EMBO J. 1998;17(23):6932-41.
[49] Steffen A, Rottner K, Ehinger J, Innocenti M, Scita G,
Wehland J, et al. Sra-1 and Nap1 link Rac to actin assembly
driving lamellipodia formation. EMBO J. 2004;23(4):749-
59.
[50] Lebensohn AM, Kirschner MW. Activation of the WAVE
complex by coincident signals controls actin assembly. Mol
Cell. 2009;36(3):512-24.
[51] An MC, Zhang N, Scott G, Montoro D, Wittkop T, Mooney
S, et al. Genetic correction of Huntington’s disease phe-
notypes in induced pluripotent stem cells. Cell Stem Cell.
2012;11(2):253-63.
[52] Valencia A, Sapp E, Kimm JS, McClory H, Reeves PB,
Alexander J, et al. Elevated NADPH oxidase activity con-
tributes to oxidative stress and cell death in Huntington’s
disease. Hum Mol Genet. 2013;22(6):1112-31.
[53] Kovac B, Teo JL, Makela TP, Vallenius T. Assembly of
non-contractile dorsal stress fibers requires alpha-actinin-
1 and Rac1 in migrating and spreading cells. J Cell Sci.
2013;126(Pt 1):263-73.
[54] Greenwood JA, Theibert AB, Prestwich GD, Murphy-
Ullrich JE. Restructuring of focal adhesion plaques by
PI 3-kinase. Regulation by PtdIns (3,4,5)-p(3) binding to
alpha-actinin. J Cell Biol. 2000;150(3):627-42.
[55] Guo F, Debidda M, Yang L, Williams DA, Zheng Y. Genetic
deletion of Rac1 GTPase reveals its critical role in actin
stress fiber formation and focal adhesion complex assembly.
J Biol Chem. 2006;281(27):18652-9.
[56] Auger KR, Serunian LA, Soltoff SP, Libby P, Cantley LC.
PDGF-dependent tyrosine phosphorylation stimulates pro-
duction of novel polyphosphoinositides in intact cells. Cell.
1989;57(1):167-75.
A. Tousley et al. / Huntingtin Modulates Rac1 Activity 69
[57] Takenawa T, Suetsugu S. The WASP-WAVE protein net-
work: Connecting the membrane to the cytoskeleton. Nat
Rev Mol Cell Biol. 2007;8(1):37-48.
[58] Tolias KF, Cantley LC, Carpenter CL. Rho family
GTPases bind to phosphoinositide kinases. J Biol Chem.
1995;270(30):17656-9.
[59] Ratovitski T, Chighladze E, Arbez N, Boronina T, Herbrich
S, Cole RN, et al. Huntingtin protein interactions altered
by polyglutamine expansion as determined by quantitative
proteomic analysis. Cell Cycle. 2012;11(10):2006-21.
[60] Kwan W, Trager U, Davalos D, Chou A, Bouchard J, Andre
R, et al. Mutant huntingtin impairs immune cell migration in
Huntington disease. J Clin Invest. 2012;122(12):4737-47.
[61] McClory H, Wang X, Sapp E, Gatune LW, Iuliano M, Wu
CY, et al. The COOH-terminal domain of huntingtin inter-
acts with RhoGEF kalirin and modulates cell survival. Sci
Rep. 2018;8(1):8000.
[62] Puigdellivol M, Cherubini M, Brito V, Giralt A, Suelves
N, Ballesteros J, et al. A role for Kalirin-7 in corticostri-
atal synaptic dysfunction in Huntington’s disease. Hum Mol
Genet. 2015;24(25):7265-85.
[63] Brito V, Giralt A, Enriquez-Barreto L, Puigdellivol M,
Suelves N, Zamora-Moratalla A, et al. Neurotrophin
receptor p75(NTR) mediates Huntington’s disease-
associated synaptic and memory dysfunction. J Clin Invest.
2014;124(10):4411-28.
[64] Suelves N, Miguez A, Lopez-Benito S, Barriga GG,
Giralt A, Alvarez-Periel E, et al. Early downregulation
of p75(NTR) by genetic and pharmacological approaches
delays the onset of motor deficits and striatal dysfunction
in Huntington’s disease mice. Mol Neurobiol. 2018; doi:
10.1007/s12035-018-1126-5.
[65] Corbetta S, Gualdoni S, Ciceri G, Monari M, Zuc-
caro E, Tybulewicz VL, et al. Essential role of Rac1
and Rac3 GTPases in neuronal development. FASEB J.
2009;23(5):1347-57.
[66] Gualdoni S, Albertinazzi C, Corbetta S, Valtorta F, de Curtis
I. Normal levels of Rac1 are important for dendritic but
not axonal development in hippocampal neurons. Biol Cell.
2007;99(8):455-64.
[67] Zhang H, Webb DJ, Asmussen H, Niu S, Horwitz AF.
A GIT1/PIX/Rac/PAK signaling module regulates spine
morphogenesis and synapse formation through MLC. J Neu-
rosci. 2005;25(13):3379-88.
[68] Ma XM, Kiraly DD, Gaier ED, Wang Y, Kim EJ, Levine
ES, et al. Kalirin-7 is required for synaptic structure and
function. J Neurosci. 2008;28(47):12368-82.
[69] Xie Z, Srivastava DP, Photowala H, Kai L, Cahill ME,
Woolfrey KM, et al. Kalirin-7 controls activity-dependent
structural and functional plasticity of dendritic spines. Neu-
ron. 2007;56(4):640-56.
[70] Chakrabarti K, Lin R, Schiller NI, Wang Y, Koubi D, Fan
YX, et al. Critical role for Kalirin in nerve growth factor
signaling through TrkA. Mol Cell Biol. 2005;25(12):5106-
18.
[71] Luo L, Hensch TK, Ackerman L, Barbel S, Jan LY, Jan
YN. Differential effects of the Rac GTPase on Purk-
inje cell axons and dendritic trunks and spines. Nature.
1996;379(6568):837-40.
[72] McKinstry SU, Karadeniz YB, Worthington AK,
Hayrapetyan VY, Ozlu MI, Serafin-Molina K, et al.
Huntingtin is required for normal excitatory synapse devel-
opment in cortical and striatal circuits. J Neurosci. 2014;
34(28):9455-72.
[73] Ferrante RJ, Kowall NW, Richardson EP, Jr. Proliferative
and degenerative changes in striatal spiny neurons in Hunt-
ington’s disease: A combined study using the section-Golgi
method and calbindin D28k immunocytochemistry. J Neu-
rosci. 1991;11(12):3877-87.
[74] Graveland GA, Williams RS, DiFiglia M. Evidence
for degenerative and regenerative changes in neostri-
atal spiny neurons in Huntington’s disease. Science.
1985;227(4688):770-3.
[75] Sotrel A, Paskevich PA, Kiely DK, Bird ED, Williams RS,
Myers RH. Morphometric analysis of the prefrontal cortex
in Huntington’s disease. Neurology. 1991;41(7):1117-23.
[76] HD iPSC Consortium. Induced pluripotent stem cells
from patients with Huntington’s disease show CAG-
repeat-expansion-associated phenotypes. Cell Stem Cell.
2012;11(2):264-78.
